Tagged with Manufacturing,

Tunisia Inès Fradi, general manager of the DPM (Directory of the Pharmacy and Medicine in Tunisia), explains the particularities of the Tunisian healthcare system and the work of the DPM in regulatory affairs as well as its interactions with the other private and public entities. She presents the recent achievements of…

Austria Ard van der Meij, country president of Novartis Group Austria, the nation’s leading pharmaceutical company, discusses the advantages in Austria for innovative companies and the steps required to bolster the generics and biosimilars market share within the Austrian market to create a sustainable healthcare ecosystem for the long-term. Furthermore, he…

Austria Prof. Dr. Robin Rumler, country manager of Pfizer Austria, discusses the evolution of their operations, especially since taking over the TBE and meningitis vaccine production plant, as well as the challenges facing the entire Austrian healthcare system today. Furthermore, he provides solutions to create a sustainable future for Austrian healthcare,…

Austria Philipp von Lattorff, country managing director of Boehringer Ingelheim’s Regional Centre Vienna (RCV) discusses the current mandate of the center and the dynamic performance of its 33 members, as well as providing an overview of the soon to be completed 700 million EUR biopharmaceutical production plant to be built in…

Ukraine Dmytro Popov, the owner, founder and CEO Elfa Group, Ukraine’s leading cosmetics manufacturer, provides his insight into Elfa’s 20-year presence in the Ukrainian market, the company’s international growth strategies and how it can further strengthen its market positioning. Could you begin by introducing yourself and your company? “Our goal is…

Ukraine Dr. Paul Melekhov, vice president Eastern Europe at Pharmascience, Canada’s third largest generic company, provides insights into the unique history of Pharmascience in Ukraine and the pioneering market approach that he has been implementing in the country over the past 25 years. Leveraging its long-standing experience of the Ukrainian market,…

Indonesia Marlia Hayati and Joey Romana, President Director and Vice President Director at PT Darya-Varia Laboratoria, share insights about the company’s strong brand equity and pioneering manufacturing strategy. In 2016, the sales growth rate achieved by Darya-Varia Laboratoria was 11 percent, above market average. What business approach is the secret to…

Hong Kong William Lai YF, CEO of Fortune Pharmacal, discusses the Hong Kong OTC market, the company’s internationalization strategy, and its expanding manufacturing footprint. Could you please introduce us to Fortune Pharmacal? What sets you apart from other OTC companies? “We follow the highest standards by always exploring what the ‘big boys’…

Ukraine Anatoliy Novyk, founder and president of SMC Ecopharm, the only Ukrainian pharmaceutical company to be exclusively focused on its own original drug development, provides insights into Ecopharm’s promising expansion strategy, which should be significantly propelled by the company’s upcoming GMP-certified manufacturing plant. He also provides an in-depth look into their…

Ukraine Filya Zhebrovska, chairman of the supervisory board of Farmak and the company’s general director between 1995 and 2017, provides insights into the strategy she has followed to establish Farmak as Ukraine’s largest domestic company and the market leader in the country since 2010. She also documents the impact of the…

Ukraine Anatoliy Reder, founder and general director of InterChem, provides insights into the heightened international ambitions of this leading, science-based Ukrainian pharmaceutical company, which plans to leverage its unique R&D and manufacturing capacities to bring to the EU and other international markets their in-house developed, original products, which proudly stand as…

Ukraine Eugene Zaika, general director Ukraine and CIS of Pharma Start, a company acquired in October 2015 by Swiss-headquartered Acino Group and one of the leading players in Ukraine, provides insights into the group’s countercyclical investments in Ukraine, while Pharma Start’s ongoing successes prove that the risk taken is actually paying…